The PATHWAY HER2 (4B5) test helps identify patients with previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC) who may be eligible for treatment with ZIIHERA.
Our HPV self-collection solution was recognized and our pTau217 assay* was also mentioned in the Medical Care category, among 200 overall Best Invention recipients. These medical innovations aim to make cervical-cancer screening and Alzheimer's diagnosis more accessible and effective.
*The pTau217 assay is available for research use only, not for use in diagnostic procedures. A similar version of the assay is under development and received FDA Breakthrough Device Designation.
The new VENTANA CLDN18 (43-14A) RxDx Assay helps fulfill an unmet medical need by enabling clinicians to identify patients with gastric or gastroesophageal junction (GEJ) cancer.
Now, HCPs will be able to detect and differentiate these respiratory viruses within a single patient visit, enabling improved public health outcomes.
Learn more about our portfolio of lab instruments, systems, assays and more
More than 800,000 documents available on demand — always up-to-date with 24/7 access
